NDA 216490 · Ascendis Pharma Bone
Yorvipath
Palopegteriparatide · Subcutaneous
NovelPriority reviewOrphanCDER novel approval, Aug 9, 2024: To treat hypoparathyroidism
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 9, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 2 recruiting
FAERS reports
462
163 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 3, 2026.
YORVIPATH is indicated for the treatment of hypoparathyroidism in adults. YORVIPATH is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. ( 1 ) Limitations of Use : Not studied for acute post-surgical hypoparathyroidism. ( 1 ) Titration scheme only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment. ( 1 ) Limitations of Use YORVIPATH was not studied for acute post-surgical hypoparathyroidism. YORVIPATH's titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment [see Dosage and Administration (2.3 , 2.4) and Clinical Studies (14) ] .
Mechanism: At physiological conditions, palopegteriparatide releases PTH(1-34) to maintain a continuous systemic exposure. Endogenous PTH maintains extracellular calcium and phosphate homeostasis by increasing serum calcium and decreasing serum phosphate. These effects are mediated by stimulating bone turnover to mobilize calcium and phosphate from bone, promoting renal calcium reabsorption and phosphate excretion, and facilitating active vitamin D synthesis, in turn increasing intestinal absorption of calcium and phosphate. Similar to endogenous PTH, PTH(1-34) released from palopegteriparatide exerts...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 9, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
- YORVIPATH · PALOPEGTERIPARATIDE EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- YORVIPATH · PALOPEGTERIPARATIDE EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) · SOLUTION, SUBCUTANEOUS · Prescription
- YORVIPATH · PALOPEGTERIPARATIDE EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Palopegteriparatide" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hypocalcaemia85
- hypercalcaemia51
- injection site reaction40
- nausea31
- blood calcium decreased28
- headache27
- dizziness23
- fatigue22
- paraesthesia21
- wrong technique in device usage process19
- product dose omission issue17
- vomiting15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 1 |
| 2024 | 8 |
| 2025 | 98 |
| 2026 | 352 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.
Clarke BL, Khan AA, Rubin MR, et al. · J Clin Endocrinol Metab 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA, Rubin MR, Schwarz P, et al. · J Bone Miner Res 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
Rejnmark L, Gosmanova EO, Khan AA, et al. · Adv Ther 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sustained improvement in renal function with palopegteriparatide in adults with chronic hypoparathyroidism: 2-year results from the phase 3 PaTHway-trial.
Rejnmark L, Gosmanova EO, Khan AA, et al. · J Bone Miner Res 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension.
Rubin M, Palermo A, Vokes T, et al. · J Clin Endocrinol Metab 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial.
Rubin MR, Clarke BL, Hofbauer LC, et al. · J Bone Miner Res 2026 · Randomized Controlled Trial
Sponsor: Ascendis Pharma Bone
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.